2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2930

Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Abstract Number: 2931

Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?
Abstract Number: 2932

A Retrospective Observational Study of Patients with Lupus Nephritis Treated with Rituximab in Combination with Cyclophosphamide
Abstract Number: 2933

Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse
Abstract Number: 2934

Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon
Abstract Number: 2935

Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)
Abstract Number: 2936

Evolution of Disease Burden over 7 Years in a Multicentre Inception SLE Cohort
Abstract Number: 2937

Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis
Abstract Number: 2938

Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Abstract Number: 2939

The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials
Abstract Number: 2940

Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)
Abstract Number: 2941

Outcomes in Lupus Nephritis Patients Previously Randomized to Receive Either Low Dose Cyclophosphamide Versus Oral Mycophenolate Mofetil on Azathioprine Maintenance
Abstract Number: 2942

Longitudinal Analyses of Progression of Brain Athrophy in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2943

Preliminary Population-Based Incidence and Prevalence Estimates of Systemic Lupus Erythematous from the Manhattan Lupus Surveillance Program
Abstract Number: 2944

Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].